What every developer should know to maximize BTD value by Dr. Jason Mercer, Ph.D., RAC and Strategic Program Innovator The Food and Drug Administration’s (FDA’s) Breakthrough Therapy Designation (BTD) program offers spons...
BTD/Orphan
Key Challenges with Orphan Drug Development for Rare Disease Treatments
By Lisa Jenkins VanLuvanee, Ph.D. Per the US FDA, orphan drugs address rare diseases affecting fewer than 200,000 people in the United States. Developing these therapies presents challenges beyond typical drug development. The ...
gET sOCIAL